JPMorgan Chase & Co. Boosts Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

JPMorgan Chase & Co. raised its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 46.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 807,483 shares of the medical instruments supplier's stock after purchasing an additional 254,322 shares during the quarter. JPMorgan Chase & Co. owned 2.00% of AngioDynamics worth $7,397,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Segall Bryant & Hamill LLC increased its holdings in AngioDynamics by 55.3% during the 4th quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier's stock worth $12,963,000 after purchasing an additional 503,713 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of AngioDynamics by 69.0% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 389,053 shares of the medical instruments supplier's stock valued at $3,564,000 after buying an additional 158,897 shares during the last quarter. Royce & Associates LP boosted its position in shares of AngioDynamics by 13.5% during the fourth quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier's stock valued at $10,254,000 after buying an additional 133,312 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in AngioDynamics in the 4th quarter valued at $879,000. Finally, Geode Capital Management LLC raised its position in AngioDynamics by 5.1% in the 3rd quarter. Geode Capital Management LLC now owns 960,767 shares of the medical instruments supplier's stock valued at $7,477,000 after buying an additional 46,409 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Stock Performance

NASDAQ ANGO traded up $0.05 on Tuesday, hitting $9.30. 312,854 shares of the stock traded hands, compared to its average volume of 561,883. The business's fifty day moving average is $9.61 and its two-hundred day moving average is $9.06. AngioDynamics, Inc. has a 12 month low of $5.47 and a 12 month high of $13.50. The firm has a market capitalization of $377.65 million, a price-to-earnings ratio of -1.65 and a beta of 0.52.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.16. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company had revenue of $72.00 million during the quarter, compared to the consensus estimate of $70.30 million. The business's revenue was down 4.3% compared to the same quarter last year. Analysts expect that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $16.00 price objective (up previously from $15.00) on shares of AngioDynamics in a report on Monday, April 7th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.